Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dongmei Quan
Institutions:
Guilin Medical University,
The Sixth People's Hospital of Shenyang
Observed institutions:
Guilin Medical University,
Liaoning University of Traditional Chinese Medicine,
The Sixth People's Hospital of Shenyang
ORCID:
0000-0002-5361-1484
Observed ORCID:
0000-0002-5361-1484
OpenAlex ID:
A5080640473
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
2025
·
Jian Zhou
, Li Bai
, et al.
·
The Lancet Oncology
·
77
Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults
2021
·
Guoyuan Sui
, Lianqun Jia
, et al.
·
Aging
·
34
PDF
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial
2025
·
Xiang'an Wu
, Dongmei Quan
, et al.
·
Gut
·
26
PDF
Multi-omics analysis of the tumor microenvironment after metastasis: advancing toward personalized immunotherapy and molecular targeted strategies
2025
·
Qing Gao
, Huqiang Wu
, et al.
·
Frontiers in Immunology
·
20
PDF
Investigating the role of GTPase in inhibiting HBV replication and enhancing interferon therapy efficacy in chronic hepatitis B patients
2024
·
Dongmei Quan
, Pengfei Wang
, et al.
·
Microbial Pathogenesis
·
2
691 First-in-human trial of novel HBsAg-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma
2023
·
Xueshuai Wan
, Wei Wu
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Antiviral and antitumor activity of SCG101, an autologous HBV-specific T cell receptor engineered T cell (TCR-T) therapy in HBV-related advanced hepatocellular carcinoma (HCC) patients after receiving ≥2 prior lines of systemic therapies
2022
·
Shunda Du
, Yuhong Zhou
, et al.
·
Journal of Hepatology
·
1
Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study.
2026
·
Chenchen Zhao
, Dongmei Quan
, et al.
·
Journal of Clinical Oncology
In vitro study on the synergistic effect of curcumin and PD98059 on anti-hepatocarcinoma and antitumor immune escape
2026
·
Xueting Wan
, Caixia Yi
, et al.
·
Cytotechnology
First-in-human Clinical Results of a Novel HBV-specific TCR T Cell Therapy (SCG101) in Patients With HBV-related Hepatocellular Carcinoma (HCC)
2025
·
Xueshuai Wan
, Wei Wu
, et al.
·
Zeitschrift für Gastroenterologie
The Associations of Dietary Index for Gut Microbiota and Genetically Predicted Gut Microbiome with the Risks of Non-Alcoholic Fatty Liver Disease and Cirrhosis: A Cohort Study
2025
·
Chenying Wang
, Dongmei Quan
, et al.
·
SSRN Electronic Journal
LBP-042 First-in-human clinical result of a novel HBV-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma (HCC)
2024
·
Xueshuai Wan
, Wei Wu
, et al.
·
Journal of Hepatology
Show more works
View as search
Works count:
13
Citation count:
162
H-index:
4
I10-index:
4
Year
Topic
Type